Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 7, 2003 - Issue 6
Submit an article Journal homepage
66
Views
19
CrossRef citations to date
0
Altmetric
Review

Novel therapeutic targets in Helicobacter pylori

Michael F Loughlin Institute of Infection, Immunity and Inflammation, Queens Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK
Pages 725-735 | Published online: 02 Mar 2005

Bibliography

  • SEPULVEDA AR, COELHO LG: Helicobacter pylori and gastric malignancies. Helicobacter (2002) 7:37–42.
  • •Review of research examining links between H pylori infection and cancers, including work using microarray technology.
  • DUNN BE, COHEN H, BLASER MJ: Helicobacter pylori. Clin. Microbic] Rev (1997) 10:720–741.
  • GODDARD AF: Getting to the route of Helicobacter pylori treatment. j Antimicrob. Cheinother: (1998) 42:1–3.
  • •Excellent summary of the challenges faced by antibiotics used against H pylorL
  • BAZZOLI F, POZZATO P, ROKKAS T: Helicobacter pylori: the challenge in therapy. Helicobacter (2002) 7:43–49.
  • •An attempt to cover the wide field of therapy in H pylori infection, including antibiotic resistance.
  • MEGRAUD F: Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology (1998) 115:1278–1282.
  • VAN DER WOUDEN EJ, THIJIS JC, VANZ WET AA, SLUITER WJ, KLEIBEUKER JH: The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti- Helicobacter pylori regimens: a meta-analysis. Am. J. Gastroenterol (1999) 94:1751–1759.
  • AHUJA V, DHAR A, BAL C, SHARMA MP: Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country. Aliment. Pharamcol. The]: (1998) 12 (6):551–555.
  • HORII T, MASE K, SUZUKI Y et al: Antibacterial activities of i3 lactamase inhibitors associated with morphological changes of cell wall in HelicobacterpylorL Helicobacter (2002) 7(1)39–45.
  • OSATO MS, REDDY SG, PIERGIES AA, BOCHENEK WJ, TESTSA RT, GRAHAM DY: Comparative efficacy of new investigational agents against Helicobacter pylori. Aliment. Pharmacol. Thec (2001) 15(4):487–492.
  • AKRITOPOULOU-ZANZE I, SOWIN TJ: Solid-phase synthesis of macrolide analogues. Comb. Chem. (2001) 3(3):301–311.
  • GISBERT JP, PAJARES JM, RACZ I: Therapy. Curr: Opin. Gastroenterol (2001) 17:S47–S54.
  • ISOMOTO H, INOUE K, FURUSU H et al.: Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacterpylori. Helicobacter (2003) 8(2):111–119.
  • SORBA F, BERTINARIA M, DI STILO A et al.: Anti-Helicobacter pylori agents endowed with H2-antagonist properties. Bioolg. Med. Chem. Lett. (2001)11(3):403–406.
  • GISBERT JP, CALVET X, BUJANDA L, MARCOS S, GISBERT JL, PAJAR JM: 'Rescue' therapy with rifabutin after multiple Helicobacter pylori failure. Helicobacter (2003) 8(2)90–94.
  • JENKS PJ: Helicobacter pylori: towards new therapeutic targets. J. Med. Microbiol (2001) 50:485–488.
  • MACKAY WG, WILLIAMS CL, MCMILLAN M, NDIP RN, SHEPHERD AJ, WEAVER LT: Evaluation of protocol using gene capture and PCR for detection of Helicobacter pylori DNA in feces. J. Clin. Microbiol (2003) 41(10):4589–4593.
  • LASCOLS C, LAMARQUE D, COSTA JM et al.: Fast and accurate quantitative detection of Helicobacter pylori and identification of clarithromycin resistance mutations in H pylori isolates from gastric biopsy specimens by real-time PCR. J. Chit. Micirthiol (2003) 41(10):4573–4577.
  • TOMB JF, WHITE 0, KERLAVAGE AR et al: The complete genome sequence of the gastric pathogen HelicobactenpylorL Nature (1997) 388:539–547.
  • ••[18] and [19] are works describing the genetic code of H pylori strains 26696 and J771. Much, if not all, future work in some way owes a debt to these papers.
  • ALM RA, LING LS, MOIR DT et al.: Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori Nature (1999) 397:176–180.
  • ••[18] and [19] are works describing thegenetic code of H pylori strains 26696 and J771. Much, if not all, future work in some way owes a debt to these papers.
  • HUGHES D: Exploiting genomics, genetics and chemistry to combat antibiotic resistance. Nat. Rev Genet. (2003) 4:432–441.
  • ••Detailed and wide-ranging discussionabout the molecular techniques currently being used to combat the problem of antibiotic resistance.
  • BJORKHOLM BM, OH JD, FALK PG, ENGSTRAND LG, GORDON JI: Genomics and proteomics converge on HeliCObaCter py1011. CUTE Opin. Microbiol (2001) 4:237–245.
  • ••Exhaustive review of techniques used toinvestigate H pylori
  • PARKINSON T: The impact of genomics on anti-infectives drug discovery and development. Trends Microbiol (2002) 10(10):522–526.
  • •Succinct summary of the range of techniques currently in use in drug discovery.
  • SALAMA N, GUILLEMIN K, MCDANIEL TK, SHERLOCK G, TOMPKINS L, FALKOW S: A whole-genome microarray reveals genetic diversity among Helicobacter pylori strains. Proc. Nat] Acad. Sci. USA (2000) 97:14668–14673
  • ••Work characterising strain-specific genesamong clinical isolates.
  • PIZZA M, SCARLATO V, MASIGNANI V et al: Identification of vaccine-candidates against serogroup B meningococcus by whole genome sequencing. Science (2000) 287:1816–1820.
  • MONTIGIANI S, FALUGI F, SCARSELLI M et al: Genomic approach for the analysis of surface proteins in Chlamydia pneumoniae. Infect. Immun. (2002) 70:368–379.
  • GRANDI G: Rational antibacterial vaccine design through genomic technologies. Int. Parasita (2003) 33:615–620.
  • ALM RA, BINA J, ANDREWS BM, DOIG P, HANCOCK RE, TRUST TJ: Comparative genomics of He/icobacter analysis of the outer membrane protein families. Infect. Immun. (2000) 68:4155–4168.
  • THYE T, BURCHARD GD, NILIUS M, MULLER-MYSHOK B, HORSTMANN RD: Genomewide linkage analysis identifies polymorphism in the human interferon-y receptor affecting Helicobacter pylori infection. Am. J. Hum. Genet. (2003) 72:448–453.
  • FIGUEIREDO C, MACHADO JC, PHAROAH P et al: Helicobacter pylori and interleukin-1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J. Natl. Cancer Inst. (2002) 94(22):1680–1687.
  • CHALKER AF, MINEHART HW, HUGHES NJ et al: Systematic identification of selective essential genes in Helicobacter pylori by genome prioritisation and allelic replacement mutagenesis. Bacteria (2001) 183:1259–1268.
  • ••Comparative genomics to select genes inH pylori that are divergent from those in other bacteria, coupled with targeted mutagenesis to determine the importance of the selected genes.
  • HENSEL M, SHEA JE, GLEESON C, JONES MD, DALTON E, HOLDEN DW: Simultaneous identification of bacterial virulence genes by negative selection. Science (1995) 269:400–403.
  • ••Original use of STM.
  • KAVERMANN H, BURNS B, ANGERMULLER K et al: Identification and characterization of Helicobacter pylori genes essential for gastric colonization. J. Exp. Med. (2003) 197(7):813–822.
  • ••First use of STM in investigating H pylon
  • GUO BP, MEKALANOS JJ: Rapid genetic analysis of Helicobacter pylori gastric mucosal colonization in suckling mice. Proc. Natl. Acad. Sci USA (2002) 99(2):8354–8359.
  • WANG J, LORY S, RAMPHAL R, JIN S: Isolation and characterisation of Pseudomonas aeruginosa genes inducible by respiratory mucus derived from cystic fibrosis patients. Ma. Microbia (1996) 22(5):1005–1012.
  • STAIB P, KRETSCHMAR M, NICHTERLEIN T et al: Host-induced, stage-specific virulence gene activation in Candida albicans during infection. Ma Microbia (1999) 32(3):533–546.
  • SLAUCH JM, CAMILLI A: IVET and RIVET: the use of gene fusions to identify bacterial virulence factors specifically induced in host tissues. Methods EnzymoL (2000) 326:73–96.
  • MORISE M, SHIMOMURA 0, JOHNSON FH, WINANT J: Intermolecular energy transfer in the bioluminescent system of Aequorea. Biochemistry (1974) 13:2656–2662.
  • MARRA A, ASUNDI J, BARTILSON M et al: Differential fluorescence induction analysis of Streptococcus pneumoniae identifies genes involved in pathogenesis. Infect. Immun. (2002) 70(3):1422–1433.
  • BONGAERTS RJ, HAUTEFORT I, SIDEBOTHAM JM, HINTON JC: Green fluorescent protein as a marker for conditional gene expression in bacterial cells. Methods Enzyma (2002) 358:43–66.
  • JOSENHANS C, FRIEDRICH S, SUERBAUM S: Green fluorescent protein as a novel marker and reporter system in Helicobacter sp. FEMS Microbia Lett. (1998) 161:263–273.
  • VALDIVIA RH, FALKOW S: Bacterial genetics by flow cytometry: rapid isolation of Salmonella Ophimurium acid-inducible promoters by differential fluorescence induction. MoL Microbia (1996) 22(2):367–378.
  • ISRAEL DA, SALAMA N, ARNOLD CN et al: Helicobacter pylori strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses.' Clin. Invest (2001) 107:611–620.
  • •Use of microarray technology to determine differences in the gene content of strains inducing different pathological responses in rodent models.
  • THOMPSON LJ, MERRELL DS, NEILAN BA, MITCHELL H, LEE A, FALKOW S: Gene expression profiling of Helicobacter pylori reveals growth-phase-dependent switch in virulence gene expression. Infect. Immun. (2003) 71(5):2643–2655.
  • •Work showing the use of microarray technology in examining changes in the transciptome at different points in the growth phase. If substantiated, it may have Important consequences for future work of this kind.
  • MERRELL DS, GOODRICH ML, OTTO G, TOMPKINS LS, FALKOW S: pH-regulated gene expression of the gastric pathogen Helicobacter pylori. Infect. Immun. (2003) 71(6):3529–3539.
  • •Recent work showing the use of microarray technology in examining changes in transcribed genes due to shifts in environment.
  • JOSENHANS C, NIEHUS E, AMERSBACH S et al: Functional characterization of the antagonistic flagellar late regulators FliA and FlgM of Helicobacter pylori and their effects on the H pylori transcriptome. Mol Microbia (2002) 43 (2):307–322.
  • WAIDNER B, MELCHERS K, IVANOV I et al: Identification by RNA profiling and mutational analysis of the novel copper resistance determinants CrdA (HP1326), CrdB (HP1327), and CzcB (HP1328) in Helicobacter pylori. J. Bacteria (2002) 184(23):6700–6708.
  • CONTRERAS M, THIBERGE JM, MANDRAND-BERTHELOT MA, LABIGNE A: Characterization of the roles of NikR, a nickel-responsive pleiotropic autoregulator of Helicobacter pylori. Ma. Microbia (2003) 49(4):947–963.
  • THOMPSON LJ, DE REUSE H: Genomics of Helicobacter pylori. Helicobacter (2002) 7:1–7.
  • ••Excellent overview.
  • SCHOOLNIK GK: Functional and comparative genomics of pathogenic bacteria. Curl: Opin. Microbia (2002) 5:20–26.
  • •Review of selected work using microarray technology with a section on H pylori genomic diversity between strains.
  • SEPULVEDA AR, TAO H, CARLONI E, SEPULVEDA J, GRAHAM DY, PETERSON LE: Screening of gene expression profiles in gastric epithelial cells induced by Helicobacter pylori using microarray analysis. Aliment. Pharmacol The]: (2002) 16(2):145–157.
  • LIM JW, KIM H, KIM KH: Cell adhesion-related gene expression by Helicobacter pylori in gastric epithelia AGS cells. Int. J. Biochem. Cell Biol. (2003) 35:1284–1296.
  • JIANG W, BAKER HJ, SMITH BF: Mucosal immunization with Helicabactec CpG DNA, and cholera toxin is protective. Infect. Iminun. (2003) 71(0:40–46.
  • MCATEE CP, FRY KE, BERG DE: Identification of potential diagnostic and vaccine candidates of Helicobacter pylori by `proteome' technologies. Helicobacter (1998) 3(3):163–169.
  • •Use of proteome techniques in the search for vaccine candidates.
  • MCATEE CP, LIM MY, FUNG K et al: Characterization of a Helicobacter pylori candidate by proteome techniques. Chromatogr. B Bioined. Sci. Appl. (1998) 714:325–333.
  • MCATEE CP, HOFFAMN PS, BERG DE: Identification of differentially regulated proteins in metronidazole-resistant Helicobacter pylori by proteome techniques. Protemnics (2001) 1(4):516–521.
  • JUNGBLUT PR, BUMANN D, HAAS G et al: Comparative proteome analysis of Helicobacter pylori. Mol Microbiol (2000) 26(3):710–725.
  • BUMANN D, AKSU S, WENDLAND M et al: Proteome analysis of secreted proteins of the gastric pathogen Helicobacter pylori. Infect. Iminun. (2002) 70(7):3396–3403.
  • •Excellent example of the use of proteomic techniques in examining specific aspects of H
  • HYNES SO, MCGUIRE J, WADSTROM T: Potential for proteomic profiling of Helicobacter pylori and other Helicobacterspp. using a Proteinchip° array. FEMS Iminunol Med. Microbiol (2003) 36:151–158.
  • •[58] and [59] both show the latest uses of proteome technology in comparing different Helicobacter species, and also in examining areas of proteomes unable to be resolved by classical 2DE.
  • HYNES SO, MCGUIRE J, FALT T, WADSTROM T: The rapid detection of low molecular mass proteins differentially expressed under biological stress for four Helicobacter spp. Using Proteinchip° technology. Protemnics (2003) 3:273–278.
  • •[58] and [59] both show the latest uses of proteome technology in comparing different Helicobacter species, and also in examining areas of proteomes unable to be resolved by classical 2DE.
  • SCHMID MB: Structural proteomics: the potential of high-throughput structure determination. Trends Microbiol (2002) 10(10):S27–S31.
  • •Excellent review of the topic.
  • ABAGYAN R, TOTROV M: High-throughput docking for lead generation. Curr. Opin. Chem. Biol. (2001) 5(4):375–382.
  • RAIN JC, SELIG L, DE REUSE H et al.: The protein-protein interaction map of Helicobacter pylori. Nature (2001) 409:211–215.
  • ••The very first comprehensive analysis ofprotein-protein interactions in a prokaryote.
  • BOCK JR, GOUGH DA: Whole-proteome interaction mining. Bioinformatics (2003) 19(1):125–135.
  • LAZOWSKA I, TRZECIAK L, GODLEWSKA R et al: In search of immunogenic Helicobacter pylori proteins by screening of expression library. Digestion (2000) 61(1):14–21.
  • HOUIMEL M, MACH JP, CORTHESY-THEULAZ I, VORTHESY B, FISCH I: New inhibitors of Helicobacter pyloriurease holoenzyme selected from phage-displayed peptide libraries. Eur. Biochem. (1999) 262:774–780.
  • CHRISTENSEN DJ, GOTTLIN EB, BENSON RE, HAMILTON PT: Phage display for target-based antibacterial drug discovery. Drug Discov. Today (2001) 6(14):721–727.
  • •Clear and concise report dealing with the technology described.
  • COVACCI A, RAPPUOLI R: Helicobacter pylori: after the genomes, back to biology. J. Exp. Med (2003) 197(7):807–811.
  • •Timely piece examining the progress made in exploring the biology of H pylori using genome-based technology.
  • HAQUE TS, TADESSE S, MARCINKEVICIENE J et al: Parallel synthesis of potent, pyrazole-based inhibitors of Helicobacter pylori dihydroorotate dehydrogenase. J. Med. Chem. (2002) 45(20:4669–4678.
  • CHUNG JG, CHEN GW, WU LT et al: Effects of garlic compounds diallyl sulfide and diallyl disulfide on arylamine N-acetyltransferase activity in strains of Helicobacter pylori from peptic ulcer patients. Am. J. Chin. Med. (1998) 26(3-4):353–364.
  • OHSAKI A, TAKASHIMA J, CHIBA N, KAWAMURA M: Microanalysis of a selective potent anti- Helicobacter pylori compound in a Brazillian medicinal plant, Myroxy/onperinkrum and the activity of analogues. Bioorg. Med. Chem. Lett. (1999) 9(8):1109–1112.
  • MICHETTI P, KREISS C, KOTLOFF KL et al.: Oral immunization with urease and Escherichia coil heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology (1999) 116(4):804–812.
  • SOUGIOULTZIS S, LEE CK, ALSAHLI M et al.: Safety and efficacy of E. roll enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine (2002) 21(3-4):194–201.
  • LEE CK, SOIKE K, HILL J et al: Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. Vaccine (1999) 17(17):1493–1505.
  • DIPETRILLO MD, TIBBETTS T, KLEANTHOUS H, KILLEEN KP, HOHMANN EL: Safety and immunogenicity of phoR phoQ-deleted Salmonella Ophi expressing Helicobacter pylori urease in adult volunteers. Vaccine (1999) 18:449–459.
  • BUMANN D, METZGER WG, MANSOURI E et al: Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine (2001) 20:845–852.
  • PRINZ C, HAFSI N, VOLAND P: Helicobacter pylori virulence factors and the host immune response: implications for therapeutic therapy. Trends Microbiol (2003) 11(3):134–138.
  • ••Exhaustive and up-to-date review of thecurrent status in the search for a H pylori vaccine.
  • LEE CK: Vaccination against Helicobacter pylori in non-human primate models and humans. Scand. Immunol (2001) 53:437–442.
  • OHTA T, SHIBATA H, KAWAMORI T, IIMURO M, SUGIMURA T, WAKABAYASHI K: Marked reduction of Helicobacter pylori-induced gastritis by urease inhibitors, acetohydroxamic acid and flurofamide, in Mongolian gerbils. Biochem. Biophys. Res. Commun. (2001) 285:728–733.
  • SACHS G, SCOTT DR, WEEKS DL, REKTORSCHECK M, MELCHERS K: Regulation of urease for acid habitation. In: Helicobacter pylori: Physiology and Genetics. Mobley HLT, Mendz GL, Hazell SL (Eds), ASM Press, Washington DC, USA (2001)25:277–283.
  • •Comprehensive review on the role of UreI in acid resistance.

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.